Achieve Life Sciences Inc
NASDAQ:ACHV
Intrinsic Value
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. [ Read More ]
The intrinsic value of one ACHV stock under the Base Case scenario is 10.66 USD. Compared to the current market price of 5.32 USD, Achieve Life Sciences Inc is Undervalued by 50%.
Valuation Backtest
Achieve Life Sciences Inc
Run backtest to discover the historical profit from buying and selling ACHV stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Balance Sheet Decomposition
Achieve Life Sciences Inc
Current Assets | 67.7m |
Cash & Short-Term Investments | 66.4m |
Other Current Assets | 1.3m |
Non-Current Assets | 2.3m |
PP&E | 51k |
Intangibles | 2.2m |
Other Non-Current Assets | 94k |
Current Liabilities | 20.6m |
Accounts Payable | 373k |
Accrued Liabilities | 2.5m |
Other Current Liabilities | 17.7m |
Earnings Waterfall
Achieve Life Sciences Inc
Revenue
|
0
USD
|
Operating Expenses
|
-24.6m
USD
|
Operating Income
|
-24.6m
USD
|
Other Expenses
|
-2.7m
USD
|
Net Income
|
-27.3m
USD
|
Free Cash Flow Analysis
Achieve Life Sciences Inc
USD | |
Free Cash Flow | USD |
ACHV Profitability Score
Profitability Due Diligence
Achieve Life Sciences Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Achieve Life Sciences Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ACHV Solvency Score
Solvency Due Diligence
Achieve Life Sciences Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Achieve Life Sciences Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ACHV Price Targets Summary
Achieve Life Sciences Inc
According to Wall Street analysts, the average 1-year price target for ACHV is 19.25 USD with a low forecast of 10.1 USD and a high forecast of 31.5 USD.
Ownership
ACHV Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ACHV Price
Achieve Life Sciences Inc
Average Annual Return | -43.86% |
Standard Deviation of Annual Returns | 41.69% |
Max Drawdown | -97% |
Market Capitalization | 182.2m USD |
Shares Outstanding | 34 341 300 |
Percentage of Shares Shorted | 2.85% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 16 full-time employees. The firm is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. The firm is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties. The Company’s has two prescription oral treatments for smoking cessation are available in the United States: Chantix (varenicline) and Zyban (bupropion).
Contact
IPO
Employees
Officers
The intrinsic value of one ACHV stock under the Base Case scenario is 10.66 USD.
Compared to the current market price of 5.32 USD, Achieve Life Sciences Inc is Undervalued by 50%.